| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
|
Ann Intern Med
|
2013
|
2.84
|
|
2
|
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
|
Hepatology
|
2011
|
1.68
|
|
3
|
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
|
Hepatology
|
2008
|
1.64
|
|
4
|
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
|
Hepatology
|
2006
|
1.62
|
|
5
|
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
|
Gut
|
2006
|
1.59
|
|
6
|
Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection.
|
Am J Gastroenterol
|
2008
|
1.54
|
|
7
|
Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
|
J Gastroenterol Hepatol
|
2010
|
1.54
|
|
8
|
OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases.
|
FASEB J
|
2011
|
1.53
|
|
9
|
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
|
Antivir Ther
|
2006
|
1.48
|
|
10
|
Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.
|
J Clin Virol
|
2013
|
1.45
|
|
11
|
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.
|
J Infect Dis
|
2010
|
1.34
|
|
12
|
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
|
Liver Int
|
2011
|
1.33
|
|
13
|
Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
|
Antivir Ther
|
2005
|
1.20
|
|
14
|
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
|
J Hepatol
|
2011
|
1.18
|
|
15
|
Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication.
|
Am J Gastroenterol
|
2007
|
1.10
|
|
16
|
The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C.
|
Gut
|
2007
|
1.10
|
|
17
|
The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies.
|
Gut
|
2007
|
1.08
|
|
18
|
Intestinal parasitic infection detected by stool examination in foreign laborers in Kaohsiung.
|
Kaohsiung J Med Sci
|
2010
|
1.06
|
|
19
|
Viral hepatitis infections in southern Taiwan: a multicenter community-based study.
|
Kaohsiung J Med Sci
|
2010
|
1.02
|
|
20
|
Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population.
|
Oral Oncol
|
2008
|
1.01
|
|
21
|
Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
|
Antiviral Res
|
2011
|
1.00
|
|
22
|
Treatment of chronic hepatitis C in southern Taiwan.
|
Intervirology
|
2006
|
0.99
|
|
23
|
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
|
Liver Int
|
2006
|
0.98
|
|
24
|
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
|
Hepatology
|
2013
|
0.97
|
|
25
|
Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1.
|
J Cell Sci
|
2011
|
0.94
|
|
26
|
Etiology, severity and recurrence of acute pancreatitis in southern taiwan.
|
J Formos Med Assoc
|
2006
|
0.92
|
|
27
|
Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection.
|
J Infect Dis
|
2003
|
0.92
|
|
28
|
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
|
J Infect Dis
|
2010
|
0.90
|
|
29
|
Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study.
|
Medicine (Baltimore)
|
2003
|
0.90
|
|
30
|
Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan.
|
Jpn J Infect Dis
|
2007
|
0.89
|
|
31
|
Genetic predisposition of responsiveness to therapy for chronic hepatitis C.
|
Pharmacogenomics
|
2006
|
0.89
|
|
32
|
Independent and additive interactive effects among tumor necrosis factor-alpha polymorphisms, substance use habits, and chronic hepatitis B and hepatitis C virus infection on risk for hepatocellular carcinoma.
|
Medicine (Baltimore)
|
2009
|
0.88
|
|
33
|
Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.
|
Neoplasia
|
2007
|
0.88
|
|
34
|
Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.
|
Hepatol Int
|
2010
|
0.87
|
|
35
|
Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients.
|
J Gastroenterol Hepatol
|
2007
|
0.87
|
|
36
|
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
|
Antivir Ther
|
2006
|
0.87
|
|
37
|
Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.
|
PLoS One
|
2012
|
0.86
|
|
38
|
Hepatitis C virus infection and metabolic syndrome---a community-based study in an endemic area of Taiwan.
|
Kaohsiung J Med Sci
|
2009
|
0.86
|
|
39
|
Glucose abnormalities in hepatitis C virus infection.
|
Kaohsiung J Med Sci
|
2012
|
0.86
|
|
40
|
Habitual betel quid chewing and risk for hepatocellular carcinoma complicating cirrhosis.
|
Medicine (Baltimore)
|
2004
|
0.86
|
|
41
|
Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma.
|
Indian J Gastroenterol
|
2012
|
0.85
|
|
42
|
Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection.
|
Hepatol Res
|
2011
|
0.84
|
|
43
|
The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy.
|
Liver Int
|
2012
|
0.84
|
|
44
|
Prevalence and clinical significance of HGV/GBV-C infection in patients with chronic hepatitis B or C.
|
Jpn J Infect Dis
|
2006
|
0.84
|
|
45
|
Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.
|
Medicine (Baltimore)
|
2015
|
0.84
|
|
46
|
Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
|
J Gastroenterol Hepatol
|
2013
|
0.83
|
|
47
|
High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study.
|
BMC Infect Dis
|
2005
|
0.83
|
|
48
|
HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study.
|
Prev Med
|
2009
|
0.83
|
|
49
|
Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin.
|
Antimicrob Agents Chemother
|
2005
|
0.83
|
|
50
|
Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.
|
PLoS One
|
2013
|
0.82
|
|
51
|
The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
|
J Hepatol
|
2010
|
0.82
|
|
52
|
Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA.
|
Scand J Infect Dis
|
2009
|
0.82
|
|
53
|
Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C.
|
J Hepatol
|
2008
|
0.82
|
|
54
|
Long-term effects of interferon-based therapy for chronic hepatitis C.
|
Oncology
|
2007
|
0.82
|
|
55
|
Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups.
|
Kaohsiung J Med Sci
|
2011
|
0.82
|
|
56
|
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
|
J Gastroenterol Hepatol
|
2014
|
0.82
|
|
57
|
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.
|
Hepatol Int
|
2010
|
0.82
|
|
58
|
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy.
|
Medicine (Baltimore)
|
2016
|
0.81
|
|
59
|
Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha.
|
Antiviral Res
|
2003
|
0.81
|
|
60
|
Abnormal liver function test predicts type 2 diabetes: a community-based prospective study: response to Cho et al.
|
Diabetes Care
|
2008
|
0.81
|
|
61
|
Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients.
|
Hepatology
|
2011
|
0.81
|
|
62
|
SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan.
|
Digestion
|
2007
|
0.81
|
|
63
|
Comparison of clinical application of the Abbott HBV PCR kit and the VERSANT HBV DNA 3.0 test to measure serum hepatitis B virus DNA in Taiwanese patients.
|
Kaohsiung J Med Sci
|
2009
|
0.81
|
|
64
|
Clinical application of serum C-reactive protein measurement in the detection of bacterial infection in patients with liver cirrhosis.
|
Kaohsiung J Med Sci
|
2002
|
0.81
|
|
65
|
Heat shock protein A1B 1267 polymorphism is highly associated with risk and prognosis of hepatocellular carcinoma: a case-control study.
|
Medicine (Baltimore)
|
2008
|
0.80
|
|
66
|
Hepatitis C virus infection among children in aboriginal areas in Taiwan.
|
Trans R Soc Trop Med Hyg
|
2008
|
0.80
|
|
67
|
Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
|
Liver Int
|
2011
|
0.80
|
|
68
|
A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors.
|
Antiviral Res
|
2004
|
0.79
|
|
69
|
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
|
PLoS One
|
2011
|
0.79
|
|
70
|
Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
|
Transl Res
|
2006
|
0.79
|
|
71
|
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
|
J Gastroenterol Hepatol
|
2011
|
0.79
|
|
72
|
Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients.
|
Kaohsiung J Med Sci
|
2012
|
0.78
|
|
73
|
Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL.
|
Hepatology
|
2009
|
0.78
|
|
74
|
Waist circumference, body mass index, serum uric acid, blood sugar, and triglyceride levels are important risk factors for abnormal liver function tests in the Taiwanese population.
|
Kaohsiung J Med Sci
|
2012
|
0.78
|
|
75
|
Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan.
|
Trans R Soc Trop Med Hyg
|
2008
|
0.78
|
|
76
|
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.
|
Medicine (Baltimore)
|
2015
|
0.77
|
|
77
|
Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals.
|
Hepatology
|
2011
|
0.77
|
|
78
|
A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
|
Liver Int
|
2006
|
0.77
|
|
79
|
Treatment uptake of patients with chronic hepatitis C: can we expect and do more?
|
Dig Dis Sci
|
2010
|
0.77
|
|
80
|
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
|
Hepatology
|
2008
|
0.76
|
|
81
|
Impact of chronic hepatitis B and hepatitis C on adverse hepatic fibrosis in hepatocellular carcinoma related to betel quid chewing.
|
Asian Pac J Cancer Prev
|
2014
|
0.76
|
|
82
|
Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients.
|
Medicine (Baltimore)
|
2016
|
0.76
|
|
83
|
Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
|
Liver Int
|
2004
|
0.76
|
|
84
|
Urinary transforming growth factor α and serum α-fetoprotein as tumor markers of hepatocellular carcinoma.
|
Tumour Biol
|
2013
|
0.76
|
|
85
|
Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan.
|
Hepatol Int
|
2010
|
0.76
|
|
86
|
Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2.
|
Hepatology
|
2008
|
0.75
|
|
87
|
Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier.
|
Hepatology
|
2011
|
0.75
|
|
88
|
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivity.
|
J Hepatol
|
2008
|
0.75
|
|
89
|
Unveiling glucose abnormalities in patients with chronic hepatitis C infection.
|
Am J Gastroenterol
|
2009
|
0.75
|
|
90
|
Links between triglyceride levels, hepatitis C virus infection and diabetes.
|
Gut
|
2007
|
0.75
|
|
91
|
Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure.
|
Hepatology
|
2008
|
0.75
|
|
92
|
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues.
|
Hepatology
|
2008
|
0.75
|
|
93
|
Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
|
Hepatology
|
2009
|
0.75
|
|
94
|
Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection.
|
Gut
|
2010
|
0.75
|
|
95
|
A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.
|
Hepatology
|
2009
|
0.75
|
|
96
|
Revisit of oral glucose tolerance test: a must for diagnosis of type 2 diabetes in patients with chronic hepatitis C.
|
Am J Gastroenterol
|
2008
|
0.75
|
|
97
|
Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
|
Hepatology
|
2011
|
0.75
|
|
98
|
The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
|
Am J Gastroenterol
|
2009
|
0.75
|
|
99
|
Prevention of donor to recipient transmission of HCV in stem cell transplantation: some issues.
|
Am J Gastroenterol
|
2007
|
0.75
|
|
100
|
High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al.
|
Diabetes Care
|
2008
|
0.75
|
|
101
|
Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0.
|
Kaohsiung J Med Sci
|
2007
|
0.75
|
|
102
|
Diagnosis of icteric-type hepatocellular carcinoma by fine needle aspiration: a case report.
|
Acta Cytol
|
2006
|
0.75
|
|
103
|
Insight into alcohol consumption-related problems and its correlates among Taiwanese alcoholic hepatogastroenterological clinic patients.
|
Subst Use Misuse
|
2009
|
0.75
|
|
104
|
Chemically-induced hepatitis in a Taiwanese male construction worker.
|
Occup Med (Lond)
|
2002
|
0.75
|
|
105
|
Toxic Metals Increase Serum Tumor Necrosis Factor-α Levels, Modified by Essential Elements and Different Types of Tumor Necrosis Factor-α Promoter Single-nucleotide Polymorphisms.
|
Epidemiology
|
2017
|
0.75
|
|
106
|
Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections.
|
Clin Chem Lab Med
|
2008
|
0.75
|
|
107
|
Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
108
|
Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses.
|
Hepatology
|
2010
|
0.75
|
|
109
|
Independent and additive interaction between tumor necrosis factor β +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study.
|
Asian Pac J Cancer Prev
|
2014
|
0.75
|
|
110
|
Novel quasi-subgenotype D2 of hepatitis B virus identified in Taiwanese aborigines.
|
Virus Genes
|
2014
|
0.75
|